Nurix Therapeutics reports Q3 FY2024 net loss $49M, $0.67 per share; cash $457.5M

Nurix Therapeutics, Inc.

2024-Q3 EPS reported -$2.13 revenue$41,265,000

Net loss $49.0M ($0.67 per share) vs $37.0M ($0.68 per share) in Q3 FY2023.
Collaboration revenue $12.6M, down from $18.5M, reflecting end of Gilead research term offset by Pfizer deal.
Cash and marketable securities $457.5M as of Aug 31, 2024, up from $452.5M at May 31, 2024.
NX-5948 Phase 1b expansion started in CLL, Waldenstrom's, follicular, marginal zone lymphoma; FDA Fast Track for CLL.
NX-2127 enrollment reinitiated with new chirally controlled drug product after FDA partial clinical hold lift.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.